Abiraterone decanoate depot
Term · Oncology and biomedicine · MLC-T-ONC-009581
A depot formulation containing the decanoate ester of abiraterone, a steroidal compound with antiandrogen activity. Upon administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This suppresses testosterone production by both the testes and the adrenals to castrate-range levels. This may decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells.
| Identifier | MLC-T-ONC-009581 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | PRL-02 depot |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009581",
"term": "Abiraterone decanoate depot",
"field": "Oncology and biomedicine",
"definition": "A depot formulation containing the decanoate ester of abiraterone, a steroidal compound with antiandrogen activity. Upon administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This suppresses testosterone production by both the testes and the adrenals to castrate-range levels. This may decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells.",
"synonyms": [
"PRL-02 depot"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/abiraterone-decanoate-depot/"
}
Record 177 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.